AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10392351 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) during induction
Number of subjects: 14
Study 10392351 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) at the end of CNS-directed therapy
Number of subjects: 14
Study 10392351 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-chemotherapy
Number of subjects: 14
Study 10392351 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil count above 1 x 10(9)/l during continuation chemotherapy
Number of subjects: 14
Study 10392351 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil count less than 1 x 10(9)/l during continuation chemotherapy
Number of subjects: 14
Study 8540453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil group (4 g/day of fish oil concentrate)
Number of subjects: 610
Study 8540453 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 610
Study 8540453 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire patient group
Number of subjects: 610
Study 1860286 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolin rinse
Number of subjects: 0
Study 1860286 — intervention group
Group type: COMPARATOR
Intervention: Saline rinse (Control)
Number of subjects: 0
Study 1860286 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine rinse (Control)
Number of subjects: 0
Study 28342045 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver (30 cm of water for 30 sec)
Number of subjects: 21
Study 28342045 — intervention group
Group type: COMPARATOR
Intervention: Sham maneuver (5 cm of water for 30 sec)
Number of subjects: 21
Study 28342045 — intervention group
Group type: EXPERIMENTAL
Intervention: Both maneuvers
Number of subjects: 21
Study 25946099 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric contact lens correction (ACUVUE MOIST for Astigmatism)
Number of subjects: 11
Study 25946099 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical contact lens correction (ACUVUE MOIST)
Number of subjects: 11
Study 25946099 — intervention group
Group type: COMPARATOR
Intervention: No correction
Number of subjects: 11
Study 23348760 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with relapsing-remitting MS
Number of subjects: 24
Study 23348760 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 24
Study 21327529 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic consult intervention
Number of subjects: 0
Study 21327529 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 19564670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure wound therapy (NPWT) at lower pressures (‐75 mm Hg or ‐100 mm Hg)
Number of subjects: 0
Study 19564670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent therapy
Number of subjects: 0
Study 19564670 — intervention group
Group type: COMPARATOR
Intervention: Continuous negative pressure wound therapy (NPWT) at higher pressure (‐125 mm Hg)
Number of subjects: 0
Study 17520151 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of keratin peptide treatment
Number of subjects: 0
Study 17520151 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of keratin-active formulation
Number of subjects: 0
Study 14732296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (final concentration 0.1, 1.0, and 10 mmol/L)
Number of subjects: 26
Study 14732296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11683967 — intervention group
Group type: COMPARATOR
Intervention: Intravesical BCG therapy (21 patients)
Number of subjects: 42
Study 11683967 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C plus doxorubicin therapy (21 patients)
Number of subjects: 42
Study 11683967 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent instillation of the other intravesical therapy for non-responders
Number of subjects: 42
Study 11683967 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies (BCG and mitomycin C plus doxorubicin)
Number of subjects: 42
Study 9843104 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 400 mg daily for 5 days
Number of subjects: 22
Study 9843104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7857507 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract LI 160 (300 mg three times daily)
Number of subjects: 12
Study 7857507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2672476 — intervention group
Group type: EXPERIMENTAL
Intervention: Invagination of the appendix stump
Number of subjects: 130
Study 2672476 — intervention group
Group type: COMPARATOR
Intervention: Simple ligature of the appendix stump
Number of subjects: 130
Study 356720 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3, 2 g/day)
Number of subjects: 15
Study 356720 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium p-chlorphenoxyisobutyrate (Ca-CPIB, 2 g/day)
Number of subjects: 15
Study 356720 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CaCO3 and Ca-CPIB
Number of subjects: 15
Study 356720 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium p-chlorphenoxyisobutyrate (Ca-CPIB, either singly or in combination)
Number of subjects: 15
Study 30012022 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-mounted gaming home exercises (20 minutes per day for one month)
Number of subjects: 47
Study 30012022 — intervention group
Group type: COMPARATOR
Intervention: Conventional vestibular rehabilitation
Number of subjects: 47
Study 30012022 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-mounted gaming home exercises
Number of subjects: 47
Study 24711350 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEAD intervention (adapted from ASSIST)
Number of subjects: 0
Study 24711350 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26318778 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 113
Study 26318778 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 113
Study 24195867 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 374
Study 24195867 — intervention group
Group type: COMPARATOR
Intervention: Print intervention
Number of subjects: 374
Study 21672267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral Performance Category (CPC) score determined using the entire hospital record
Number of subjects: 131
Study 21672267 — intervention group
Group type: COMPARATOR
Intervention: Cerebral Performance Category (CPC) score determined using the discharge summary alone
Number of subjects: 131
Study 21672267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral Performance Category (CPC) score with survival to hospital discharge of 20%
Number of subjects: 131
Study 21672267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral Performance Category (CPC) score with survival to hospital discharge of 30%
Number of subjects: 131
Study 18644067 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) group
Number of subjects: 30
Study 18644067 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 16488346 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial hydration (1L or more per day)
Number of subjects: 125
Study 16488346 — intervention group
Group type: COMPARATOR
Intervention: Nonhydration (no artificial hydration)
Number of subjects: 125
Study 16488346 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated fluid balance
Number of subjects: 125
Study 16488346 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial hydration
Number of subjects: 125
Study 12779198 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous metoclopramide 8-hourly for 48 hours
Number of subjects: 22
Study 12779198 — intervention group
Group type: COMPARATOR
Intervention: 5% saline (control) 8-hourly for 48 hours
Number of subjects: 22
Study 12779198 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous metoclopramide
Number of subjects: 22
Study 10882145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FL) 40 mg single dose
Number of subjects: 32
Study 10882145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FL) 60 mg per day for 12 weeks
Number of subjects: 32
Study 10882145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) for 12 weeks
Number of subjects: 32
Study 10882145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FL) and Placebo (PL)
Number of subjects: 32
Study 9386007 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic cortical stimulation with extension torque load of 0.35 Nm
Number of subjects: 9
Study 9386007 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic cortical stimulation with extension torque load of 0.26 Nm
Number of subjects: 9
Study 9386007 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic cortical stimulation with extension torque load of 0.18 Nm
Number of subjects: 9
Study 9386007 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic cortical stimulation with flexion torque load of 0.09 Nm
Number of subjects: 9
Study 9386007 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic cortical stimulation with flexion torque load of 0.18 Nm
Number of subjects: 9
Study 9386007 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic cortical stimulation without external load
Number of subjects: 9
Study 8260298 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 12.5 micrograms kg‐1 injected into the deltoid muscle (n = 30)
Number of subjects: 90
Study 3517250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphokine-activated killer (LAK) cells
Number of subjects: 9
Study 3517250 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Number of subjects: 9
Study 3517250 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with LAK cells and IL-2
Number of subjects: 9
Study 29908669 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 661
Study 29908669 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 661
Study 29908669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study 26527782 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib for 3 years
Number of subjects: 400
Study 26527782 — intervention group
Group type: COMPARATOR
Intervention: Imatinib for 1 year
Number of subjects: 400
Study 26527782 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib for 3 years in patients with centrally confirmed GIST without macroscopic metastases
Number of subjects: 400
Study 26527782 — intervention group
Group type: COMPARATOR
Intervention: Imatinib for 1 year in patients with centrally confirmed GIST without macroscopic metastases
Number of subjects: 400
Study 27128609 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 60 mg
Number of subjects: 26
Study 27128609 — intervention group
Group type: COMPARATOR
Intervention: Darexaban 60 mg with ketoconazole 400 mg once daily on Days 1-9
Number of subjects: 26
Study 23791510 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 23791510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20674510 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional knotless barbed suture
Number of subjects: 44
Study 20674510 — intervention group
Group type: COMPARATOR
Intervention: Continuous suture with intracorporeal knots
Number of subjects: 44
Study 19597409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 10% spray gel (360 mg/die)
Number of subjects: 41
Study 19597409 — intervention group
Group type: COMPARATOR
Intervention: Oral ketoprofen (25 mg t.i.d.)
Number of subjects: 41
Study 19597409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacological treatment)
Number of subjects: 41
Study 19597409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 10% spray gel
Number of subjects: 41
Study 15917156 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation
Number of subjects: 30
Study 15917156 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol treatment
Number of subjects: 30
Study 14601367 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha as an adjuvant treatment to preoperative autologous blood donation (PAD) program (40,000 IU weekly for 21, 14, and 7 days before surgery)
Number of subjects: 75
Study 14601367 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alpha alone (2 doses weekly for the same period)
Number of subjects: 75
Study 10773049 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet concentrates (PCs) in plasma
Number of subjects: 21
Study 10773049 — intervention group
Group type: COMPARATOR
Intervention: Platelet concentrates (PCs) in PAS‐2
Number of subjects: 21
Study 8817981 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal left heart bypass with oxygenation
Number of subjects: 25
Study 8817981 — intervention group
Group type: COMPARATOR
Intervention: Standard left heart bypass
Number of subjects: 25
Study 1332737 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 80 micrograms/kg
Number of subjects: 151
Study 1332737 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 2 mg/kg every 2 h for five doses plus dexamethasone 10 mg and diphenhydramine
Number of subjects: 151
Study 4016522 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous morphine infusion
Number of subjects: 75
Study 4016522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intramuscular morphine
Number of subjects: 75
Study 4016522 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 75
Study 30763176 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided iCBT
Number of subjects: 254
Study 30763176 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed iCBT
Number of subjects: 254
Study 30763176 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 254
Study 29390433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐kin system with additional conventional balance training for 20 minutes per session, 5 times a week, for 2 weeks
Number of subjects: 40
Study 29390433 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance training
Number of subjects: 40
Study 26135348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice for 1 week
Number of subjects: 27
Study 26135348 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (placebo) for 1 week
Number of subjects: 27
Study 23749153 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-molar sodium lactate (SL) infusion at 0.5 ml/kg/h for 48 hours
Number of subjects: 60
Study 23749153 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution (control group)
Number of subjects: 60
Study 23749153 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-molar sodium lactate (SL) infusion
Number of subjects: 60
Study 21685643 — intervention group
Group type: EXPERIMENTAL
Intervention: High-arousal virtual environment
Number of subjects: 60
Study 21685643 — intervention group
Group type: COMPARATOR
Intervention: Low-arousal virtual environment
Number of subjects: 60
Study 20113610 — intervention group
Group type: EXPERIMENTAL
Intervention: Montessori education (two-hour Montessori pedagogical activities every day)
Number of subjects: 0
Study 20113610 — intervention group
Group type: COMPARATOR
Intervention: Traditional education
Number of subjects: 0
Study 16427556 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5%) via ON-Q pain management system for 72 hours
Number of subjects: 70
Study 16427556 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (control group)
Number of subjects: 70
Study 16427556 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5%) via ON-Q pain management system
Number of subjects: 70
Study 14578367 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic hypoxia (HH)
Number of subjects: 13
Study 14578367 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 13
Study 14578367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (HH and Normoxia)
Number of subjects: 13
Study 11445478 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed-supplemented, fat-restricted diet (30 g/day flaxseed, 20% of kilocalories or less from fat)
Number of subjects: 25
Study 11445478 — intervention group
Group type: COMPARATOR
Intervention: Historic controls (matched by age, race, PSA level at diagnosis, and biopsy Gleason sum)
Number of subjects: 25
Study 9502368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 52
Study 9502368 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 8062886 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3) at doses of 0.5, 1.25, 2.5, 5.0, or 10 micrograms/kg/d by subcutaneous injection for 21-day cycles
Number of subjects: 21
Study 8062886 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3) at doses of 5.0 micrograms/kg/d or higher
Number of subjects: 21
Study 8062886 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3)
Number of subjects: 21
Study 3064773 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-preserving therapy
Number of subjects: 847
Study 3064773 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 847
Study 3064773 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized group (breast-preserving therapy)
Number of subjects: 847
Study 3064773 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized group (mastectomy)
Number of subjects: 847
Study 30728053 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS QUIK toolkit intervention
Number of subjects: 21374
Study 29146650 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron syrup (12.5 mg elemental iron)
Number of subjects: 3300
Study 29146650 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powders (MMPs including 12.5 mg elemental iron)
Number of subjects: 3300
Study 29146650 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 3300
Study 29146650 — intervention group
Group type: COMPARATOR
Intervention: Placebo MNPs
Number of subjects: 3300
Study 26686508 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-HB-Hib vaccine (3 doses with 4-week intervals)
Number of subjects: 600
Study 23582676 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder (ILR)
Number of subjects: 78
Study 23582676 — intervention group
Group type: COMPARATOR
Intervention: Conventional testing
Number of subjects: 78
Study 23582676 — intervention group
Group type: EXPERIMENTAL
Intervention: ILR
Number of subjects: 78
Study 21716986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ormocer (Admira)
Number of subjects: 84
Study 21716986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofilled composite (Filtek Supreme)
Number of subjects: 84
Study 21716986 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhybrid composite (Tetric Ceram)
Number of subjects: 84
Study 21716986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoceramic composite (CeramX mono)
Number of subjects: 84
Study 21716986 — intervention group
Group type: COMPARATOR
Intervention: Unprepared positive control
Number of subjects: 84
Study 21716986 — intervention group
Group type: COMPARATOR
Intervention: Unrestored negative control
Number of subjects: 84
Study 19822631 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemanagement
Number of subjects: 100
Study 19822631 — intervention group
Group type: COMPARATOR
Intervention: Best available care (control)
Number of subjects: 100
Study 17077434 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 327
Study 17077434 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 327
Study 17077434 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 327
Study 17077434 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 327
Study 17077434 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 327
Study 17077434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 327
Study 15080855 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 48692 (90 mg)
Number of subjects: 24
Study 15080855 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 48692 (300 mg)
Number of subjects: 24
Study 15080855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15080855 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 48692 (90 mg) and (300 mg)
Number of subjects: 24
Study 15080855 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 48692
Number of subjects: 24
Study 10662749 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]epinephrine (EPI)
Number of subjects: 17
Study 10662749 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]hydroxyephedrine (HED)
Number of subjects: 17
Study 10662749 — intervention group
Group type: COMPARATOR
Intervention: EPI
Number of subjects: 17
Study 10662749 — intervention group
Group type: COMPARATOR
Intervention: HED
Number of subjects: 17
Study 9313662 — intervention group
Group type: EXPERIMENTAL
Intervention: 130 mg free beta-sitosterol daily
Number of subjects: 177
Study 9313662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 8365079 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula (WH)
Number of subjects: 45
Study 8365079 — intervention group
Group type: COMPARATOR
Intervention: Whey-predominant formula (WF)
Number of subjects: 45
Study 2444962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of lysine
Number of subjects: 14
Study 2444962 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 14
Study 29505773 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper intrauterine device
Number of subjects: 266
Study 29505773 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate
Number of subjects: 266
Study 29505773 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate
Number of subjects: 266